Neratinib (Nerlynx™): First Global Approval – a new adjuvant option for HER2+ve breast cancer patients – but has it bottomed out before it’s begun?

Neratinib (Nerlynx™): First Global Approval – a new adjuvant option for HER2+ve breast cancer patients – but has it bottomed out before it’s begun?

The recent first global approval of neratinib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Neratinib (Nerlynx™): First Global Approval – a new adjuvant option for HER2+ve breast cancer patients – but has it bottomed out before it’s begun?”

Inotuzumab Ozogamicin (Besponsa®): First Global Approval – targeted treatment for Adults with relapsed or recurrent B-cell acute lymphoblastic leukaemia

Inotuzumab Ozogamicin (Besponsa®): First Global Approval – targeted treatment for Adults with relapsed or recurrent B-cell acute lymphoblastic leukaemia

The recent first global approval of inotuzumab ozogamicin has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Inotuzumab Ozogamicin (Besponsa®): First Global Approval – targeted treatment for Adults with relapsed or recurrent B-cell acute lymphoblastic leukaemia”

Guselkumab (Tremfya™): First Global Approval – first-in-class biologic treatment option for adult plaque psoriasis

Guselkumab (Tremfya™): First Global Approval – first-in-class biologic treatment option for adult plaque psoriasis

The recent first global approval of guselkumab has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Guselkumab (Tremfya™): First Global Approval – first-in-class biologic treatment option for adult plaque psoriasis”

Reporting Cost Effectiveness Analyses: Time for Improvement

Chris Carswell, Co-Editor in Chief, PharmacoEconomics

I am not a frequent blogger but one recurring issue has forced me to put finger to keyboard – insufficient detail and transparency in many submitted cost effectiveness analyses. Reporting checklists have been available for many years. According to Web of Science, the 1996 Drummond checklist[1] has been cited over 950 times. CHEERS[2], published in 2013, has been cited over 260 times and is one of the most downloaded Task Force Reports from the International Society of Pharmacoeconomics and Outcomes Research. In addition, authors continue to identify the need for reporting improvement to aid transparency and facilitate model replication.[3] So, why the apparent lack of compliance with well-recognized reporting checklists? Continue reading “Reporting Cost Effectiveness Analyses: Time for Improvement”

Drugs in R&D obtains ESCI indexing

The open access journal Drugs in R&D was recently included in Clarivate Analytics’ Emerging Sources Citation Index (ESCI). The ESCI only considers journals that are peer reviewed, have ethical publishing practices, meet technical requirements, have English language bibliographic information, and be recommended or requested by a scholarly audience of Web of Science users.

The ESCI was launched in 2015 and citations from the ESCI will be included in the citation counts for the Journal Citation Reports that contribute to the Impact Factors of other journals. Journals in the ESCI will be discoverable via the Web of Science with an identical indexing process to other indexed journals, including citation counts and author information. Articles in ESCI indexed journals will also be included in an author’s H-Index calculation and analyses conducted with Web of Science data and related products such as InCites.

Inclusion in ESCI will improve the visibility of a journal and provides a mark of quality which should encourage submissions from authors